Compare Lumen Technologies Inc (LUMN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Natera Inc. Common Stock — how do they compare? Lumen Technologies Inc trades at $4.52 (market cap $5.14B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 11.1× Lumen Technologies Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Natera Inc. Common Stock for 0 Days on average.
| LUMN | NTRA | |
|---|---|---|
Market Cap | $5.14B | $57.03B |
Volume | 15,538,010 | 1,131,157 |
Sector | Media | Health |
52-Week High | $11.83 | $425.64 |
52-Week Low | $4.55 | $179.42 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $16.76B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $4.55, down 9.9% in the past 24 hours, reflecting bearish technical signals and negative investor sentiment. The company reported mixed quarterly earnings, with a Q1 2026 miss but a Q2 2026 beat, while full-year 2025 revenue declined to $12.40B with a net loss of $1.74B. High debt levels and a negative ROE of -78.94% highlight financial strain, though recent strategic moves include a Nasdaq listing and new AI-focused networking services to drive growth.
The outlook remains challenging due to persistent losses and heavy debt, but deep value metrics like a low P/S of 0.42 and strategic pivots to AI connectivity offer speculative upside. Key risks include execution on growth initiatives, competitive pressures, and interest rate sensitivity. Analysts are largely cautious, with a 'Reduce' consensus, suggesting limited near-term catalysts.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
